AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04167956 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ultrasound and CT
Description: Experimental: ultrasound combined with CT guided Active Comparator: CT guided
Study NCT04167956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound and CT
Description: Experimental: ultrasound combined with CT guided Active Comparator: CT guided
Study NCT02756065 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention is used
Study NCT03230487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1 - single rising dose. Part 2 multiple rising dose
Study NCT02647047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Description: Administration of morphine 0.2 mg in subarachnoid space.
Study NCT02647047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL in epidural space
Study NCT02647047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane block
Description: Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally
Study NCT02033551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02033551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: combination of Fluorouracil, leucovorin and irinotecan
Study NCT00318838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azimilide dihydrochloride
Description: 125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
Study NCT00318838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
Study NCT04463160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prevention program for prediabetes Say No to Diabetes
Description: 10 therapeutic education sessions
Study NCT02647047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical wound infiltration
Description: Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
Study NCT02647047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours
Study NCT02647047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours
Study NCT02647047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy
Study NCT02647047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy
Study NCT02647047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Epidural bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL
Study NCT02647047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Epidural continuous epidural infusion of sufentanil 50 mcg/mL 1 mL
Study NCT02647047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally to obtain the transversus abdominis plane block
Study NCT04291417 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CBC-DIFF Monocyte Volume Width Distribution (MDW)
Description: MDW measurement used to detect sepsis. Results will not be used to manage patients.
Study NCT01380405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education intervention
Description: Individual or collective education interventions about the correct use of inhalers.~session in the management of inhalers in the collective or individual programmed.~Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons.
Study NCT03492450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training
Description: Tailored treatment comprising of: 1) aerobic exercises with the aim of increasing fitness 2) task-oriented balance exercises on the treadmill to improve balance and 3) cognitive behavioral interventions to improve balance and gait during dual task activities.In accordance with the literature (Langeskov-Christensen, 2015, Latimer-Cheung, 2013) the treadmill training will be carried out without body weight support, but the participants will be allowed to use the handrails for balance support if needed. The training consists of three different walking sessions, each lasting for 10 minutes: 1) preferred walking speed at an increased slope; 2) walking doing dynamic balance exercises (for example walking with feet in tandem) 3) fast gait speed defined as a 10% increase in walking speed relative to preferred speed with dual task exercises. During the 8-week intervention, walking speed in session 3 will be gradually increased with 10% to 40% of preferred speed.
Study NCT02134704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data recording with all sensors
Description: The sensors will be placed in the child body and will allow the collection of all the data of the trial.
Study NCT00957346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone+misoprostol
Description: single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
Study NCT00957346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+Misoprostol
Description: placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
Study NCT02647047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
Study NCT04277572 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: Aortic valve surgery
Study NCT01168804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine plus bortezomib plus dexamethasone
Description: Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
Study NCT04920461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Additional MRI sequences
Description: Additional MRI sequences (3D T2 SPACE sequence, 4/5 minutes approximatively)
Study NCT04920461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: Neurovisual function assessed with neuropsychological tests
Study NCT03545152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Prescription exercise: frequency, intensity, type, time, and progression (FITT-PRO).~150 min/week (the intensity will be moderate). exercise routine: warming up, resistance training and aerobic exercise training(range of motion and flexibility exercises)
Study NCT03545152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training intervention consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
Study NCT03545152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New life-style
Description: Combination of exercise and cognitive interventions
Study NCT02221739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT03816137 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mosaic SOSIPs
Description: Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
Study NCT02221739 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (IMRT or 3-D CRT)
Study NCT01285921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vestibular test before and after hippocampal surgery
Description: * Research of a spontaneous nystagmus with and without fixation(VIDEONYSTAGMOSCOPY) and segmentary deviations (Fukuda test)~* HIT (testing semicircular canal function at high frequency).Results: Gain in %~* VEMp (testing saccular function). Results: Amplitude in μV and latency in ms~* ERI (testing lateral semicircular function at middle frequency). Results: Nystagmus during and after the rotations in frequency and slow phase velocity (SPV) in °/s~* Caloric test (testing lateral semicircular function at low frequency). Results: Canal paresis in % and SPV in °/S
Study NCT02807116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Subjects received a single oral 400-mg dose of pacritinib
Study NCT02807116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Subjects received 600-mg oral doses of rifampin; administered QD following a 7-day washout period
Study NCT01562873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study NCT02807116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib and Rifampin
Description: On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
Study NCT02287792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18-FDG PET/CT scan
Description: Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis
Study NCT01220310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online diabetes workshop observation and learning sessions
Description: We will, by self-administered pre- and post-intervention surveys, evaluate the effectiveness of the online diabetes workshop observations and learning sessions.
Study NCT01720511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Purple Rice
Description: Incorporate one cup of purple rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
Study NCT00615082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: An 8-week course led by an experienced instructor in a group format of up to 15 people. Participants in the MBSR course learn mindfulness meditation techniques and simple yoga exercises such as stretching.
Study NCT00615082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Education & Social Support
Description: An 8-week course led by experienced instructors in a group format of up to 15 people. Participants in the CESS course learn about a variety of important issues related to elder care and receive social and emotional support in a group discussion format.
Study NCT01720511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brown Rice
Description: Incorporate one cup of brown rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
Study NCT02887105 — intervention group
Intervention type: OTHER
Intervention: Standard neuropsychological assessment
Study NCT02887105 — intervention group
Intervention type: OTHER
Intervention: Brain MRI
Study NCT02129569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Description: Receive information about strategies for cognitive self-management of distress
Study NCT00163553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pethidine
Study NCT00163553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02060396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: One tablet of Adiro 100 mg will be administered daily orally for 7 days.
Study NCT01797783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A multifocal contact lens with comfort additive
Study NCT01797783 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A multifocal contact lens
Study NCT03807999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Study NCT03807999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT03807999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT02075255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 4 weeks
Study NCT02075255 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously on study week 0 until study week 24 inclusive.
Study NCT02075255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
Study NCT02463266 — intervention group
Intervention type: BEHAVIORAL
Intervention: SUSTAIN Monitoring and Care Management
Description: Program participants are offered clinical services based on symptom severity and clinical need. Follow-up Monitoring consists of up to 4 brief, structured assessments following the baseline clinical assessment. These follow-up contacts are conducted over the telephone by the HT/BHP and take place during the initial 12 weeks of pharmaceutical treatment. These brief interviews monitor symptoms, adherence, side effects, and response to treatment. Care Management incorporates the use of a BHP who has expertise in mental health assessment and is well versed in the delivery of algorithm-based management strategies. The BHP monitors and encourages patient acceptance and adherence to treatment recommendations through support, education, and motivational engagement.
Study NCT04742517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1128
Description: Intravenous
Study NCT04742517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study NCT02853331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study NCT02853331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Oral tablet
Study NCT02853331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Oral capsule
Study NCT03464097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days
Study NCT03464097 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT00590681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Temozolomide
Description: This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
Study NCT02378428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIBG
Study NCT04452526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care
Study NCT01369485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: (VERV™ System)
Description: Active electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
Study NCT01369485 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham version of (VERV™ System)
Description: Inactive (sham) electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
Study NCT05832476 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03338309 — intervention group
Intervention type: OTHER
Intervention: Instantaneous wave-free ratio measurement
Description: Instantaneous wave-free ratio measurement in order to evaluate functional significance of epicardial stenosis
Study NCT00622076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative catheterization
Description: postoperative catheterization after anterior colporrhaphy for five days versus two days.
Study NCT00882492 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GLP 1
Description: This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)
Study NCT00882492 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: normal saline solution placebo
Description: This is a continuous intravenous infusion of normal saline solution as placebo (1.5 pmol/kg/min) during cardiac surgery
Study NCT03920384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental intervention arm
Description: Psychological therapy for psychosis with new therapy components
Study NCT03920384 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control arm
Description: Standard psychological therapy for psychosis without new therapy components
Study NCT01609101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: C-MAC ® videolaryngoscope
Description: C-MAC ® videolaryngoscope
Study NCT01609101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Coopdech® videolaryngoscope
Description: Coopdech® videolaryngoscope
Study NCT01609101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: McGrath® Series 5 videolaryngoscope
Description: McGrath® Series 5 videolaryngoscope
Study NCT01609101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Glidescope® Cobalt videolaryngoscope
Description: Glidescope® Cobalt videolaryngoscope
Study NCT01609101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: King Vision® videolaryngoscope
Description: King Vision® videolaryngoscope
Study NCT01609101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Venner® videolaryngoscope
Description: Venner® videolaryngoscope
Study NCT01609101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: McGrath® MAC
Description: McGrath® MAC (Aircraft Medical, Edinburgh, UK)
Study NCT05034445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation sequencing
Description: Extract DNA from sputum sample, minimum DNA amount should be over 50ng.
Study NCT02142114 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye injection by 30 or 32 gauge needle
Description: Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size. When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
Study NCT00905008 — intervention group
Intervention type: DEVICE
Intervention: Drug-Eluting and Bare-Metal stents
Description: Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents
Study NCT02129569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: Receive individualized walking prescription and wear pedometer
Study NCT02129569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Receive supplemental counseling support over the phone
Study NCT02129569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive NCI educational booklets and a link to the ACS website
Study NCT02129569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: telephone-based intervention
Description: Receive calls that are primarily social in nature
Study NCT02129569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02129569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies